Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

November 20, 2024

Nvidia's purchase of 7.72 million shares of Applied Digital boosted the company's revenue and earnings. Applied Digital plans to expand its data centers and AI cloud infrastructure.

Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars

November 15, 2024

Via Benzinga

Topics Artificial Intelligence

A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals

November 07, 2024

Via Benzinga

Peering Into Recursion Pharmaceuticals's Recent Short Interest

November 04, 2024

Via Benzinga

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

October 30, 2024

Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia

From Recursion Pharmaceuticals

Nvidia has disclosed an investment in Applied Digital, a digital infrastructure provider. Nvidia stock dipped while APLD stock rose.

Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes

November 15, 2024

Via Investor's Business Daily

Recursion and Exscientia Shareholders Approve the Proposed Combination

November 13, 2024

Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close

From Recursion Pharmaceuticals

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

November 12, 2024

It largely depends on your investing style.

Is Recursion Pharmaceuticals Stock a Buy?

September 20, 2024

Looking Into Recursion Pharmaceuticals's Recent Short Interest

September 16, 2024

Via Benzinga

MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday

November 11, 2024

Via Benzinga

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

November 06, 2024

From Recursion Pharmaceuticals

In an environment where the typical small biotech name is riskier than not, this one is curiously different.

10 Health Care Stocks Moving In Monday's Pre-Market Session

November 04, 2024

Via Benzinga

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

November 02, 2024

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

October 31, 2024

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

Via Benzinga

Topics ETFs Stocks

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

October 26, 2024

This company stands to benefit from a shifting pharmaceutical industry landscape.

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

October 22, 2024

The key word here is "could."

Prediction: These 2 Stocks Could Soar in 2025

October 17, 2024

Wood has a stake in this stock, but it's hardly an "all-in" bet.

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

October 15, 2024

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.

Topics Artificial Intelligence

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

October 15, 2024

Topics Artificial Intelligence

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

October 08, 2024

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

October 07, 2024

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Topics Artificial Intelligence

October 02, 2024

The Ark Invest portfolio is known for taking aggressive bets.

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

September 29, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

September 10, 2024

September 07, 2024

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

Topics Economy

September 05, 2024

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...